From the Diabetes Prevention Program Coordinating Center, the Biostatistics Center, George Washington University, Rockville, Maryland.
Diabetes Care. 2000 Nov;23(11):1619-29. doi: 10.2337/diacare.23.11.1619.
The Diabetes Prevention Program (DPP) is a 27-center randomized clinical trial designed to evaluate the safety and efficacy of interventions that may delay or prevent development of diabetes in people at increased risk for type 2 diabetes.
Eligibility requirements were age > or = 25 years, BMI > or = 24 kg/m2 (> or = 22 kg/m2 for Asian-Americans), and impaired glucose tolerance plus a fasting plasma glucose of 5.3-6.9 mmol/l (or < or = 6.9 mmol for American Indians). Randomization of participants into the DPP over 2.7 years ended in June 1999. Baseline data for the three treatment groups--intensive lifestyle modification, standard care plus metformin, and standard care plus placebo--are presented for the 3,234 participants who have been randomized.
Of all participants, 55% were Caucasian, 20% were African-American, 16% were Hispanic, 5% were American Indian, and 4% were Asian-American. Their average age at entry was 51 +/- 10.7 years (mean +/- SD), and 67.7% were women. Moreover, 16% were < 40 years of age, and 20% were > or = 60 years of age. Of the women, 48% were postmenopausal. Men and women had similar frequencies of history of hypercholesterolemia (37 and 33%, respectively) or hypertension (29 and 26%, respectively). On the basis of fasting lipid determinations, 54% of men and 40% of women fit National Cholesterol Education Program criteria for abnormal lipid profiles. More men than women were current or former cigarette smokers or had a history of coronary heart disease. Furthermore, 66% of men and 71% of women had a first-degree relative with diabetes. Overall, BMI averaged 34.0 +/- 6.7 kg/m2 at baseline with 57% of the men and 73% of women having a BMI > or = 30 kg/m2. Average fasting plasma glucose (6.0 +/- 0.5 mmol/l) and HbA1c (5.9 +/- 0.5%) in men were comparable with values in women (5.9 +/- 0.4 mmol/l and 5.9 +/- 0.5%, respectively).
The DPP has successfully randomized a large cohort of participants with a wide distribution of age, obesity, and ethnic and racial backgrounds who are at high risk for developing type 2 diabetes. The study will examine the effects of interventions on the development of diabetes.
糖尿病预防计划(DPP)是一项由27个中心参与的随机临床试验,旨在评估可能延缓或预防2型糖尿病高危人群患糖尿病的干预措施的安全性和有效性。
入选标准为年龄≥25岁,体重指数(BMI)≥24kg/m²(亚裔美国人≥22kg/m²),糖耐量受损且空腹血糖为5.3 - 6.9mmol/L(美国印第安人≤6.9mmol/L)。1999年6月结束了为期2.7年的将参与者随机分配至DPP的工作。本文给出了已被随机分组的3234名参与者在三个治疗组(强化生活方式干预、标准治疗加二甲双胍、标准治疗加安慰剂)的基线数据。
所有参与者中,55%为白种人,20%为非裔美国人,16%为西班牙裔,5%为美国印第安人,4%为亚裔美国人。他们入组时的平均年龄为51±10.7岁(均值±标准差),67.7%为女性。此外,16%年龄<40岁,20%年龄≥60岁。女性中48%已绝经。男性和女性高胆固醇血症病史(分别为37%和33%)或高血压病史(分别为29%和26%)的发生率相似。根据空腹血脂测定结果,54%的男性和40%的女性符合美国国家胆固醇教育计划的血脂异常标准。当前或曾经吸烟或有冠心病病史的男性多于女性。此外,66%的男性和71%的女性有患糖尿病的一级亲属。总体而言,基线时BMI平均为34.0±6.7kg/m²,57%的男性和73%的女性BMI≥30kg/m²。男性的平均空腹血糖(6.0±0.5mmol/L)和糖化血红蛋白(HbA1c,5.9±0.5%)与女性的值相当(分别为5.9±0.4mmol/L和5.9±0.5%)。
糖尿病预防计划成功地将一大群年龄、肥胖程度以及种族和民族背景分布广泛的2型糖尿病高危参与者进行了随机分组。该研究将检验干预措施对糖尿病发生的影响。